Navigation Links
Major Imaging Initiative to Shed Light on Little Known Brain Disease
Date:1/25/2010

UCSF scientists have received a $10 million grant from the National Institutes of Health to embark on a major neuroimaging study of a degenerative brain disease that is at least as common as Alzheimer’s disease in people under age 6

(Vocus) January 25, 2010 -- UCSF scientists have received a $10 million grant from the National Institutes of Health to embark on a major neuroimaging study of a degenerative brain disease that is at least as common as Alzheimer’s disease in people under age 60.

The fatal disease, known as frontotemporal dementia, affects decision-making, behavior, emotion and language. It gradually destroys the ability to behave in a socially appropriate manner, to empathize with others, learn, reason, make judgments, communicate and carry out daily activities. Because of the changes in personality that occur, the disease is perplexing for loved ones before a diagnosis is made and remains a particularly distressing disorder to manage. Some patients, as a result of their disease, mishandle money, commit adultery and carry out criminal behaviors, such as embezzlement.

Scientists have identified several mutated genes associated with the various forms of the disease, each of which in its own way leads to destruction of nerve cells in the frontal and temporal lobes of the brain. However, there are no therapies targeting the proteins the gene’s produce, though a multi-institutional trial is under way to test a drug that targets some of the disease’s symptoms.

The current study, led by Howard Rosen, MD, UCSF associate professor of neurology, is intended to determine how to use new imaging techniques to illuminate the changes that occur in the brain as the disease progresses. This information will enable scientists to identify biomarkers for diagnosis and, most importantly, track the impact of experimental drugs.

“Having accurate measures of the normal rates of change in FTD will be critical for planning future medication trials that will use imaging as an outcome,” says Rosen.

“While cognitive testing scores vary from day to day due to factors such as sleep quality and medication use, imaging studies measure brain structure and function precisely. They can reveal when a drug has slowed or reversed the brain shrinkage that would normally occur.”

UCSF and the Mayo Clinic in Rochester, Minnesota, will collaborate to enroll 120 FTD patients, as well as about 80 people who will serve as cognitively normal “controls.” Each participant will be followed for one and a half years with neurological examinations, cognitive and behavioral assessments, and brain imaging. Neurologist David Knopman, MD, will lead the Mayo team.

FTD is diagnosed by an assessment of a patient’s clinical history, and by neurological, cognitive and behavioral evaluations. Blood tests and neuroimaging supplement the process, but primarily help rule out other neurological disorders and provide additional evidence for FTD, rather than reveal a definitive diagnosis.

The new imaging project, which will begin in early 2010, will obtain several different types of images in each patient. Some will be obtained through structural magnetic resonance imaging, which measures the size and shape of the brain, and positron emission tomography, which examines aspects of metabolism, such as glucose consumption. Others will be obtained through promising new MRI techniques, including imaging to measure the blood content in the brain, and imaging to determine the integrity of the neural wiring, or axons, connecting various parts of the brain, using a technique called diffusion tensor imaging.

“It is possible that one or both of these techniques could replace PET scanning, which is expensive and requires exposure to radiation,” says Rosen. “This would lower the cost of clinical trials and make it possible for more patients to enroll because MRI scanners are commonly available.”

The study will investigate whether a combination of images, such as structural MRI, PET and DTI, will provide a better explanation of how a patient is doing than any one of these image types alone. It also will include serial assessments of the chemistry in the blood and cerebrospinal fluid the surrounds the brain, to see how these relate to changes in the brain images.

The new study, known as the Frontotemporal Lobar Degeneration Neuroimaging Initiative, takes advantage of the infrastructure developed for another major NIH-funded study of which UCSF is a leader, known as the Alzheimer’s Disease Neuroimaging Initiative, says Rosen.

The ADNI, begun in 2004, established procedures that make it possible to obtain comparable images at different centers, and has established procedures for ensuring high quality data. This year, the ADNI made a significant step forward in developing a test to help diagnose the beginning stages of Alzheimer’s disease sooner and more accurately by measuring levels of two biomarkers -- tau and beta-amyloid proteins -- in cerebrospinal fluid.

The FTLDNI is funded primarily by the National Institute of Aging, and is co-funded by the National Institute of Neurological Disease and Stroke.

Related links:

UCSF Memory and Aging Center – spotlight on FTD
http://memory.ucsf.edu/ftd/

UCSF Memory and Aging Center
http://memory.ucsf.edu/

Contact:
Corinna Kaarlela, News Director
Source: Jennifer O’Brien (415) 476-2557
Web: www.ucsf.edu

###

Read the full story at http://www.prweb.com/releases/2010/01/prweb3520504.htm.


'/>"/>
Source: PRWeb
Copyright©2010 Vocus, Inc.
All rights reserved

Related medicine news :

1. The International Multiple Sclerosis Management Practice Announces Major Expansion Plans to NYC Headquarters
2. A Finnish-Swiss team cracks the atomic structure of a major cancer drug target
3. Sharing Miracles Features Major League Baseball Star Aaron Boone
4. American Lung Association Report Card: Federal Government Makes Major Strides; Most States Flunk for Neglecting to Prevent Tobacco-Caused Disease
5. Study identifies those elderly most at risk for major depression
6. Sharing Miracles Television Program to Feature Major League Baseball Star Aaron Boone
7. New Study Shows That American Public is Willing to Accept Major Reforms in Medicare Program
8. Former Senate Majority Leaders Baker, Daschle and Dole Commend Senate Passage of Health Care Bill
9. Mimotopes Awarded a Major Peptide Library Supply Agreement by La Jolla Institute for their Studies Screening Dengue and Tuberculosis Pathogens
10. Simone Announces Availability of Major Warehouse/Office Complex in the Bronx
11. New Commonwealth Fund survey of young adults finds wide majority support health reform
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/24/2017)... ... March 24, 2017 , ... The iaedp Foundation, the premier ... professionals caring for those suffering from the full spectrum of disordered eating, announced today ... disorders professionals from nearly all 50 states and several countries converged on the Green ...
(Date:3/24/2017)... ... March 24, 2017 , ... ... wanted to create a communications platform that positions them as the go-to thought ... ONS reinvented their online publication as an always-on, always-fresh news, views and advocacy ...
(Date:3/24/2017)... ... March 24, 2017 , ... Viewers who like to educate themselves on current ... practices, goods, services, and societal issues tend to appreciate and love the "Informed" series, ... of utilizing running events for causes around the world. , Running for ...
(Date:3/24/2017)... ... March 24, 2017 , ... “Finding Christ ... #TruthwithGrace”: a devotional journal chronicling the writer’s path toward true communion with God. ... with God #TruthwithGrace” is the creation of published author Lea Michelle Johnson, a ...
(Date:3/24/2017)... ... ... Adventures of Joey, The Dog Who Barks at Puddles”: a boisterous story about a ... God intended. “The Adventures of Joey, The Dog Who Barks at Puddles” is the ... writing, especially about truth and human behavior. , Published by Christian Faith Publishing, Patti ...
Breaking Medicine News(10 mins):
(Date:3/24/2017)... -- Research and Markets has announced the addition of ... 2035" report to their offering. ... The Deep Learning: Drug Discovery and Diagnostics Market, ... growing market of deep learning solutions within the healthcare domain. Primarily ... as a novel solution to generate relevant insights from medical data. ...
(Date:3/24/2017)... , March 24, 2017 ... the industry including definitions, classifications, applications and industry chain ... international market including development history, competitive landscape analysis, and ... ... industry spread across 105 pages providing 10 company profiles ...
(Date:3/24/2017)... 2017 Research and Markets has announced the ... Report" report to their offering. ... The report provides separate comprehensive analytics for the US, ... , Asia-Pacific , Latin America ... the period 2015 through 2022. Also, a six-year historic analysis is provided ...
Breaking Medicine Technology: